Based on the data derived from mechanistic studies on HS pathogenesis, clinical studies are underway to assess the effects of inhibiting other potential targets in HS patients, including targets in the IL‐17 and JAK/STAT pathway, the complement cascade, and B cells.47 This evidence concerns the gene IL17A and histiocytic sarcoma.